This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6wib
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Next generation monomeric IgG4 Fc== | ==Next generation monomeric IgG4 Fc== | ||
| - | <StructureSection load='6wib' size='340' side='right'caption='[[6wib]]' scene=''> | + | <StructureSection load='6wib' size='340' side='right'caption='[[6wib]], [[Resolution|resolution]] 2.55Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WIB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WIB FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6wib]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6WIB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6WIB FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wib FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wib OCA], [https://pdbe.org/6wib PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wib RCSB], [https://www.ebi.ac.uk/pdbsum/6wib PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wib ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wib FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wib OCA], [https://pdbe.org/6wib PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wib RCSB], [https://www.ebi.ac.uk/pdbsum/6wib PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wib ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life. | ||
| + | |||
| + | In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.,Shan L, Dyk NV, Haskins N, Cook KM, Rosenthal KL, Mazor R, Dragulin-Otto S, Jiang Y, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Oganesyan V Commun Biol. 2021 Sep 8;4(1):1048. doi: 10.1038/s42003-021-02565-5. PMID:34497355<ref>PMID:34497355</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6wib" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: | + | [[Category: Acqua, W Dall]] |
| - | [[Category: Oganesyan | + | [[Category: Dyk, N van]] |
| - | [[Category: Shan L]] | + | [[Category: Oganesyan, V Y]] |
| - | [[Category: | + | [[Category: Shan, L]] |
| + | [[Category: Antibody constant region]] | ||
| + | [[Category: Fragment crystallizable]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Mutated]] | ||
Revision as of 06:56, 22 September 2021
Next generation monomeric IgG4 Fc
| |||||||||||
